Q1 Earnings Estimate for ACTU Issued By HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Actuate Therapeutics in a research report issued to clients and investors on Monday, March 17th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Price Performance

ACTU opened at $6.99 on Wednesday. Actuate Therapeutics has a 12-month low of $5.51 and a 12-month high of $11.73. The firm has a 50 day moving average of $8.12 and a two-hundred day moving average of $8.06.

Hedge Funds Weigh In On Actuate Therapeutics

Several institutional investors have recently made changes to their positions in ACTU. Freestone Capital Holdings LLC purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $80,000. Envestnet Asset Management Inc. purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $83,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $84,000. Sigma Planning Corp purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $128,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Actuate Therapeutics in the 4th quarter valued at $130,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.